Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486281 | 0.83 | PGR (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL17486236 | 0.81 | SMN1; SMN2 (0.35) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL17486219 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL17486186 | 0.79 | CYP11B1 (0.31) | CYP11B1CYP11B2ALDH1A1HTT | |
| SCHEMBL19295077 | 0.79 | ALOX5AP (0.33) | — | |
| SCHEMBL17486200 | 0.78 | DGAT1 (0.34) | — | |
| SCHEMBL17486283 | 0.77 | IDO1 (0.35) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL17486017 | 0.75 | SMN1; SMN2 (0.33) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL17477823 | 0.73 | NPC1 (0.38) | ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL17486102 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | CYP11B1 2725/4885CYP11B2 2183/4885PTGES 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.